West Cancer Center

LUNG: NSCLC; Metastatic; Adenocarcinoma; 1st line; "IMpower 150"

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Title

Hoffman-La Roche GO29436

Study Title

Site Link

NCT02366143

Malignancy

Lung Cancer, Metastatic Lung Cancer, Non-small cell lung cancer, NSCLC, Adenocarcinoma of lung

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

1st

Investigational Agent

Atezolizumab (MPDL3280A)

Drug Class

PD-L1 inhibitor

Ari VanderWalde, MD, MPH

Sponsor

Hoffman-La Roche

Phase

Phase 3

Status

Closed to Accrual

Key Eligibility Criteria

NCT02366143

Key Eligibility Criteria Details

Metastatic non-squamous NSCLC
Treatment-naive (1st line) with following exceptions: Prior adjuvant tx at least 6 months before development of stage 4 disease; EGFR mutated cancer must have been treated with any number of anti-EGFR therapies; ALK fusions must have been treated with any number of anti-ALK therapies
ECOG PS 0-1
Previously obtained archival tissue or willingness to undergo repeat biopsy at screening
No active or untreated CNS malignancies. Pts with CNS involvement may only be enrolled if they have treated disease, all disease was supratentorial (no midbrain, medulla, or spine), and are off steroids.
No significant autoimmune disease
No prior immune checkpoint-inhibitor therapy

Objective

Primary- PFS: Secondary- ORR, OS, DoR, TTD, safety

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Adenocarcinoma, large-cell carcinoma, bronchoalveolar carcinoma

Dosing Frequency

q3 weeks

Control Agents

Bevacizuamab, Carboplatin, Paclitaxel

Study Protocol

Randomized